Clinical outcomes of palbociclib plus letrozole compared to letrozole alone in Thai hormonal receptor positive advanced breast cancer
Phase 4
Active, not recruiting
- Conditions
- metastatic breast cancer
- Registration Number
- TCTR20180920002
- Lead Sponsor
- Thai Society of Clinical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
1.metastatic breast cancer, ER+ve,Her2 -ve
2.postmenopausal state
3.measurable lesion
Exclusion Criteria
1.progression of cancer during adjuvant aromatase inhibitor or less than 1 year after completion of such treatment
2.contraindication for treatment with palbociclib
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival date of progression date of progression- date treatment started
- Secondary Outcome Measures
Name Time Method quality of life every 3 months until progression EORTC QLQ-C30 , QLQ-BR23